ASX - By Stock
|
ROG |
Re:
Ann: Innamincka - Yarrow Production Commenced
|
|
Inv2k20
|
329 |
92K |
8 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
329
|
92K
|
8
|
|
ASX - By Stock
|
ROG |
Re:
Ann: Innamincka - Yarrow Production Commenced
|
|
Inv2k20
|
329 |
92K |
13 |
19/08/23 |
19/08/23 |
ASX - By Stock
|
329
|
92K
|
13
|
|
ASX - By Stock
|
ROG |
Re:
Ann: Innamincka - Yarrow Production Commenced
|
|
Inv2k20
|
329 |
92K |
5 |
19/08/23 |
19/08/23 |
ASX - By Stock
|
329
|
92K
|
5
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
Inv2k20
|
12K |
4.3M |
32 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
12K
|
4.3M
|
32
|
|
ASX - By Stock
|
IHL |
Re:
Ann: IHL-42X positive phase 2 clinical trial results
|
|
Inv2k20
|
389 |
160K |
13 |
10/03/22 |
10/03/22 |
ASX - By Stock
|
389
|
160K
|
13
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Response to ASX Price Query
|
|
Inv2k20
|
26 |
8.6K |
7 |
19/02/21 |
19/02/21 |
ASX - By Stock
|
26
|
8.6K
|
7
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Outstanding SubB2M Ovarian Cancer Test Data
|
|
Inv2k20
|
532 |
174K |
11 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
532
|
174K
|
11
|
|
ASX - By Stock
|
BOT |
Re:
Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus
|
|
Inv2k20
|
1K |
286K |
58 |
03/02/21 |
03/02/21 |
ASX - By Stock
|
1K
|
286K
|
58
|
|
ASX - By Stock
|
PCK |
Re:
Ann: December 2020 Quarterly Update
|
|
Inv2k20
|
1 |
1.1K |
9 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
1
|
1.1K
|
9
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Appendix 4C - quarterly
|
|
Inv2k20
|
67 |
21K |
13 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
67
|
21K
|
13
|
|
ASX - By Stock
|
BOT |
Re:
Announcement date and opening price
|
|
Inv2k20
|
370 |
129K |
0 |
15/01/21 |
15/01/21 |
ASX - By Stock
|
370
|
129K
|
0
|
|
ASX - By Stock
|
BCK |
Re:
A gain of 35%
|
|
Inv2k20
|
65 |
17K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
65
|
17K
|
1
|
|
ASX - Day Trading
|
|
Re:
Morning Trading December 11
|
|
Inv2k20
|
540 |
80K |
1 |
11/12/20 |
11/12/20 |
ASX - Day Trading
|
540
|
80K
|
1
|
|
ASX - By Stock
|
IHL |
Re:
Ann: IHL initiates psilocybin clinical trial for anxiety disorder
|
|
Inv2k20
|
166 |
60K |
15 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
166
|
60K
|
15
|
|
ASX - By Stock
|
GLN |
Re:
Ann: Trading Halt
|
|
Inv2k20
|
44 |
10K |
0 |
08/10/20 |
08/10/20 |
ASX - By Stock
|
44
|
10K
|
0
|
|
ASX - By Stock
|
ROG |
Re:
ROG - Road Ahead
|
|
Inv2k20
|
154 |
64K |
5 |
18/09/20 |
18/09/20 |
ASX - By Stock
|
154
|
64K
|
5
|
|
ASX - By Stock
|
BOT |
Re:
Ann: BTX 1801 Phase 2a Antimicrobial Study Underway
|
|
Inv2k20
|
291 |
125K |
10 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
291
|
125K
|
10
|
|
ASX - By Stock
|
LEG |
Re:
Ann: Initial Director's Interest Notice
|
|
Inv2k20
|
22 |
8.0K |
1 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
22
|
8.0K
|
1
|
|
ASX - By Stock
|
PCK |
Re:
Ann: PainChek Completes $10 Million Placement
|
|
Inv2k20
|
54 |
18K |
8 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
54
|
18K
|
8
|
|
ASX - By Stock
|
PCK |
Re:
Ann: PainChek Completes $10 Million Placement
|
|
Inv2k20
|
54 |
18K |
6 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
54
|
18K
|
6
|
|
ASX - By Stock
|
PCK |
Re:
PCK's Moat / Competitive Advantage
|
|
Inv2k20
|
88 |
24K |
13 |
06/08/20 |
06/08/20 |
ASX - By Stock
|
88
|
24K
|
13
|
|
ASX - By Stock
|
BOT |
Re:
Ann: Appendix 4C - Quarterly
|
|
Inv2k20
|
62 |
23K |
2 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
62
|
23K
|
2
|
|
ASX - By Stock
|
BOT |
Re:
Ann: Appendix 4C - Quarterly
|
|
Inv2k20
|
62 |
23K |
0 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
62
|
23K
|
0
|
|
ASX - By Stock
|
IHL |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
Inv2k20
|
34 |
10K |
5 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
34
|
10K
|
5
|
|
ASX - By Stock
|
ROG |
Re:
Ann: Quarterly Activities and Cashflow Report
|
|
Inv2k20
|
1 |
1.0K |
0 |
31/07/20 |
31/07/20 |
ASX - By Stock
|
1
|
1.0K
|
0
|
|
ASX - By Stock
|
ECS |
Re:
Some action today
|
|
Inv2k20
|
10 |
2.4K |
1 |
20/07/20 |
20/07/20 |
ASX - By Stock
|
10
|
2.4K
|
1
|
|
ASX - By Stock
|
ECS |
Re:
Some action today
|
|
Inv2k20
|
10 |
2.4K |
0 |
20/07/20 |
20/07/20 |
ASX - By Stock
|
10
|
2.4K
|
0
|
|
ASX - By Stock
|
BIT |
Re:
BIT036- a likely candidate for curing COVID-19
|
|
Inv2k20
|
2.0K |
703K |
0 |
17/07/20 |
17/07/20 |
ASX - By Stock
|
2.0K
|
703K
|
0
|
|
ASX - By Stock
|
BIT |
Re:
BIT036- a likely candidate for curing COVID-19
|
|
Inv2k20
|
2.0K |
703K |
3 |
17/07/20 |
17/07/20 |
ASX - By Stock
|
2.0K
|
703K
|
3
|
|
ASX - By Stock
|
IHL |
Re:
Ann: Trading Halt
|
|
Inv2k20
|
102 |
25K |
2 |
15/07/20 |
15/07/20 |
ASX - By Stock
|
102
|
25K
|
2
|
|
ASX - By Stock
|
MEM |
Re:
General Chat
|
|
Inv2k20
|
981 |
620K |
10 |
13/07/20 |
13/07/20 |
ASX - By Stock
|
981
|
620K
|
10
|
|
ASX - By Stock
|
MEM |
Re:
General Chat
|
|
Inv2k20
|
981 |
620K |
8 |
13/07/20 |
13/07/20 |
ASX - By Stock
|
981
|
620K
|
8
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Performance rights vest on first market entry into Canada
|
|
Inv2k20
|
15 |
3.7K |
8 |
10/07/20 |
10/07/20 |
ASX - By Stock
|
15
|
3.7K
|
8
|
|
ASX - By Stock
|
BIT |
Re:
chart daily
|
|
Inv2k20
|
3.2K |
1.0M |
1 |
09/07/20 |
09/07/20 |
ASX - By Stock
|
3.2K
|
1.0M
|
1
|
|
ASX - By Stock
|
BIT |
Re:
Where are the COVID-19 results?
|
|
Inv2k20
|
91 |
34K |
12 |
09/07/20 |
09/07/20 |
ASX - By Stock
|
91
|
34K
|
12
|
|
ASX - By Stock
|
BOT |
Re:
Ann: Botanix Provides Update on Development Activities
|
|
Inv2k20
|
23 |
9.8K |
9 |
24/06/20 |
24/06/20 |
ASX - By Stock
|
23
|
9.8K
|
9
|
|
ASX - By Stock
|
PCK |
Re:
PainChek General Discussion
|
|
Inv2k20
|
20K |
16M |
0 |
09/06/20 |
09/06/20 |
ASX - By Stock
|
20K
|
16M
|
0
|
|
ASX - By Stock
|
ROG |
Re:
ROG
|
|
Inv2k20
|
77 |
32K |
2 |
04/06/20 |
04/06/20 |
ASX - By Stock
|
77
|
32K
|
2
|
|
ASX - By Stock
|
WCN |
Re:
Ann: Response to ASX Price and Volume Query
|
|
Inv2k20
|
6 |
2.6K |
9 |
03/06/20 |
03/06/20 |
ASX - By Stock
|
6
|
2.6K
|
9
|
|
ASX - By Stock
|
GLN |
Re:
General Discussion Banter GLN
|
|
Inv2k20
|
15K |
5.8M |
6 |
03/06/20 |
03/06/20 |
ASX - By Stock
|
15K
|
5.8M
|
6
|
|
ASX - By Stock
|
PCK |
Re:
June 2021 & 2022 Share Price Predictions
|
|
Inv2k20
|
178 |
66K |
5 |
29/05/20 |
29/05/20 |
ASX - By Stock
|
178
|
66K
|
5
|
|
ASX - By Stock
|
PCK |
Re:
PainChek General Discussion
|
|
Inv2k20
|
20K |
16M |
8 |
25/05/20 |
25/05/20 |
ASX - By Stock
|
20K
|
16M
|
8
|
|
ASX - By Stock
|
LEG |
Re:
Ann: Diamond and Aircore Assay Results Received from Mawson
|
|
Inv2k20
|
121 |
65K |
6 |
15/05/20 |
15/05/20 |
ASX - By Stock
|
121
|
65K
|
6
|
|
ASX - By Stock
|
LEG |
Re:
Ann: Diamond and Aircore Assay Results Received from Mawson
|
|
Inv2k20
|
121 |
65K |
12 |
15/05/20 |
15/05/20 |
ASX - By Stock
|
121
|
65K
|
12
|
|
ASX - By Stock
|
BOT |
Re:
Antimicrobial platform - BTX 1801 Phase 2a clinical study
|
|
Inv2k20
|
125 |
57K |
13 |
12/05/20 |
12/05/20 |
ASX - By Stock
|
125
|
57K
|
13
|
|
ASX - By Stock
|
PCK |
Re:
PainChek General Discussion
|
|
Inv2k20
|
20K |
16M |
19 |
11/05/20 |
11/05/20 |
ASX - By Stock
|
20K
|
16M
|
19
|
|
ASX - By Stock
|
BOT |
Re:
WHO - antibiotic resistance is one of the most urgent health challenges of our time
|
|
Inv2k20
|
13 |
6.0K |
1 |
02/05/20 |
02/05/20 |
ASX - By Stock
|
13
|
6.0K
|
1
|
|
ASX - By Stock
|
BOT |
Re:
WHO - antibiotic resistance is one of the most urgent health challenges of our time
|
|
Inv2k20
|
13 |
6.0K |
3 |
02/05/20 |
02/05/20 |
ASX - By Stock
|
13
|
6.0K
|
3
|
|
ASX - By Stock
|
BOT |
WHO - antibiotic resistance is one of the most urgent health challenges of our time
|
|
Inv2k20
|
13 |
6.0K |
26 |
02/05/20 |
02/05/20 |
ASX - By Stock
|
13
|
6.0K
|
26
|
|
ASX - By Stock
|
BOT |
Re:
Ann: Appendix 4C - Quarterly
|
|
Inv2k20
|
46 |
15K |
33 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
46
|
15K
|
33
|
|